NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Nexalin Technology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.36+0.01 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $49.90M
- P/E (TTM)
- –
- Dividend yield
- –
Nexalin Technology, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q4 21 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Equipment [Member] | $98.54K | $56.13K | $37.83K | $20.35K | $21.34K | $26.78K | – | – | – | 56.4% |
| Licensing Fee [Member] | $59.55K | $65.26K | $69.50K | $83.64K | $82.92K | $79.19K | $80.21K | $86.42K | $102.91K | 34.1% |
| Other [Member] | $16.72K | $9.68K | $5.89K | $1.48K | $9.56K | $26.41K | $39.87K | $40.33K | $937 | 9.6% |
| Device Sales [Member] | – | – | $55.50K | – | – | $1.16M | – | – | – | – |
| Royalty Fee [Member] | – | – | – | – | – | $24.48K | – | – | – | – |
By region
| Revenue | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q4 21 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $70.17K | $80.75K | $83.47K | $104.89K | $121.28K | $113.54K | $113.86K | $118.38K | $117.93K | 40.1% |
| China | – | – | – | – | – | $1.21M | $1.19M | $699.20K | $26.13K | – |
From the segment and revenue-disaggregation notes of Nexalin Technology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.